EcoR1 Capital LLC 13D and 13G filings for Aligos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 5:07 pm Purchase |
2023-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
EcoR1 Capital LLC | 290,566 9.990% |
132,631 (+83.98%) |
Filing |
| 2023-02-13 08:25 am Purchase |
2022-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
EcoR1 Capital LLC | 157,934 9.900% |
29,402 (+22.88%) |
Filing |
| 2022-02-14 4:55 pm Purchase |
2022-02-04 | 13G | Aligos Therapeutics, Inc. ALGS |
EcoR1 Capital LLC | 128,532 7.500% |
128,532 (New Position) |
Filing |